Mylofam: what changed
Two financial years side by side, explained: what moved most in the balance sheet and the result, why the result rose or fell, and where the money went.
Mylofam
Largest movements
- Receivables within one year -€14,769
down €14,769 (-1.5%), from €953,970 to €939,201
of which Trade receivables: -€43,770
- Accrued charges and deferred income -€225,000
down €225,000 (-50.0%), from €450,000 to €225,000
- Other debts +€200,000
up €200,000 (+49.9%), from €400,912 to €600,912
- Gross operating margin -€207,446
down €207,446 (-96.6%), from €214,719 to €7,273
From the 2024 result to the 2025 result
Each bar is the change in one income-statement line, as its effect on the result: higher costs pull it down, higher income lifts it.
Derived cash bridge
Derived from the 2024 and 2025 balance sheets and the 2025 result: not a filed cash-flow statement. It shows where the money came from and went.
Every line side by side
| Line | Code | 2024 | 2025 | Change | % |
|---|---|---|---|---|---|
| Total assets | 20/58 | €970,536 | €948,980 | -€21,555 | -2.2% |
| Fixed assets | 21/28 | €3,979 | €1,155 | -€2,824 | -71.0% |
| Tangible fixed assets | 22/27 | €3,979 | €1,155 | -€2,824 | -71.0% |
| Furniture and vehicles | 24 | €3,979 | €1,155 | -€2,824 | -71.0% |
| Current assets | 29/58 | €966,557 | €947,826 | -€18,731 | -1.9% |
| Amounts receivable within one year | 40/41 | €953,970 | €939,201 | -€14,769 | -1.5% |
| Trade receivables | 40 | €952,174 | €908,404 | -€43,770 | -4.6% |
| Other amounts receivable | 41 | €1,796 | €30,797 | +€29,001 | +1,615% |
| Current investments | 50/53 | €9,864 | €7,963 | -€1,901 | -19.3% |
| Cash at bank and in hand | 54/58 | €2,723 | €662 | -€2,060 | -75.7% |
| Total equity and liabilities | 10/49 | €970,536 | €948,980 | -€21,555 | -2.2% |
| Equity | 10/15 | €119,623 | €122,965 | +€3,342 | +2.8% |
| Contributions | 10/11 | €20,000 | €20,000 | = | 0.0% |
| Reserves | 13 | €153,100 | €153,100 | = | 0.0% |
| Distributable reserves | 133 | €153,100 | €153,100 | = | 0.0% |
| Profit (loss) carried forward | 14 | -€53,477 | -€50,135 | +€3,342 | +6.2% |
| Amounts payable | 17/49 | €850,912 | €826,015 | -€24,897 | -2.9% |
| Amounts payable within one year | 42/48 | €400,912 | €601,015 | +€200,103 | +49.9% |
| Trade debts | 44 | - | €103 | +€103 | |
| Suppliers | 440/4 | - | €103 | +€103 | |
| Other amounts payable | 47/48 | €400,912 | €600,912 | +€200,000 | +49.9% |
| Accrued charges and deferred income | 492/3 | €450,000 | €225,000 | -€225,000 | -50.0% |
| Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets | 630 | €3,084 | €2,824 | -€260 | -8.4% |
| Other operating charges | 640/8 | €539 | €998 | +€459 | +85.2% |
| Gross operating margin | 9900 | €214,719 | €7,273 | -€207,446 | -96.6% |
| Operating profit (loss) | 9901 | €211,095 | €3,450 | -€207,645 | -98.4% |
| Financial income | 75/76B | €1,022 | €99 | -€923 | -90.3% |
| Recurring financial income | 75 | €1,022 | €99 | -€923 | -90.3% |
| Financial charges | 65/66B | €226 | €207 | -€19 | -8.2% |
| Recurring financial charges | 65 | €226 | €207 | -€19 | -8.2% |
| Profit (loss) for the period before taxes | 9903 | €211,891 | €3,342 | -€208,549 | -98.4% |
| Income taxes | 67/77 | -€143 | €0 | +€143 | |
| Profit (loss) for the period | 9904 | €212,034 | €3,342 | -€208,692 | -98.4% |
| Profit (loss) for the period to be appropriated | 9905 | €212,034 | €3,342 | -€208,692 | -98.4% |
Source: filed annual accounts (NBB), financial years ended 31 December 2024 and 31 December 2025. Colour: green is a favourable move for that line, red an unfavourable one. Prepared on 25 October 2026 via checked.be.